IP Library › Granted Patent US 9,453,224
Granted Patent B2
US 9,453,224 · App. 14/714,470 · Granted Sep 27, 2016

MiRNA modulators of thermogenesis

Inventor: Marc Thibonnier (Austin, TX)
Assignee: AptamiR Therapeutics, Inc.
C12N15/113C12Q1/68C12N2310/141C12N2310/16C12N2310/3519C12N2320/11C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,453,224
App. No.
14/714,470
Granted
Sep 27, 2016
Kind
B2
Abstract

Provided are novel methods and compositions for the modulation of thermogenesis. Such methods are particularly advantageous in that they allow for the reduction of body fat in a subject without the subject having to adjust their caloric intake through dieting, modify their physical activity or undergo bariatric surgery. Accordingly, the methods of the invention are particularly useful for treating or preventing obesity. Also provided are methods of screening for novel agents that modulate the activity of thermogenic regulators.

Claims (14)

1. A method of modulating respiratory chain uncoupling in a cell or thermogenesis in a tissue, the method comprising contacting the cell or tissue with an antagomir of miR-22, miR-22-3p or miR-22-5p, wherein the antagomir modulates activity of at least one of UCP1 or UCP2.

2. The method of claim 1 , wherein the tissue is brown fat, white fat, subcutaneous adipose tissue, liver or muscle.

3. A method of reducing body fat in a human subject in need thereof, the method comprising administering to the human subject an effective amount of an antagomir of miR-22, miR-22-3p or miR-22-5p, wherein the antagomir modulates activity or expression of at least one of UCP1 or UCP2.

4. The method of claim 3 , wherein the human subject in need thereof is obese.

5. The method of claim 3 , wherein the miRNA agent is linked to targeting moiety.

6. The method of claim 3 , wherein the targeting moiety is an aptamer.

7. The method of claim 3 , wherein the targeting moiety delivers the miRNA agent to a specific cell type or tissue.

8. The method of claim 3 , wherein the miRNA agent directly binds to the mRNA or promoter region of at least one mitochondrial uncoupler.

9. The method of claim 3 , wherein the miRNA agent directly binds to the 5′UTR or coding sequence of the mRNA of at least one mitochondrial uncoupler.

10. The method of claim 3 , wherein the miRNA agent modulates the activity of an activator or repressor of a mitochondrial uncoupling protein.

11. The method of claim 3 , wherein the mRNA expression, protein expression, or mitochondrial uncoupling activity of the mitochondrial uncoupling protein is upregulated.

12. The method of claim 3 , wherein the antagomir is an antagomir of miR-22-3p or mir-22-5p.

13. The method of claim 12 , wherein the antagomir is an antagomir of miR-22-3p.

14. The method of claim 3 , wherein the human subject selected for treatment has a genetic or epigenetic predisposition to obesity.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2015
From: THIBONNIER, MARC
To: APTAMIR THERAPEUTICS, INC.
Reel/Frame 035657/0214 →
CHANGE OF ADDRESS Recorded May 18, 2015
From: APTAMIR THERAPEUTICS, INC.
To: APTAMIR THERAPEUTICS, INC.
Reel/Frame 035706/0573 →
Continuity (4)
Continuation 13826775 · Mar 14, 2013
Provisional Application 61636059 · Apr 20, 2012
Provisional Application 61681750 · Aug 10, 2012
Related Publication 20150329861A1 · Nov 19, 2015